Judy Garber, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses predictive and prognostic genetic testing in breast cancer, outlining who should be tested, what genes should be investigated, and how the findings could guide treatment decisions. Prof. Garber talks on how the findings of the OlympiA trial (NCT02032823) of olaparib treatment in patients with germline BRCA1/2 mutations and high-risk HER2-negative primary breast cancer could change thinking on who should be tested. This interview took place during the 17th St. Gallen International Breast Cancer Conference
